The CGTLive™ Hematology specialty topic page houses the most up-to-date clinical news coverage in the field of hematology gene and cell therapy. It also includes video interviews with key opinion leaders in the field of hematology/oncology about the latest relevant FDA actions, clinical guideline updates, and clinical trial findings related to the development of cell therapies, gene therapies, and engineered and regenerative medicines for various blood disorders.
May 15th 2024
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Medical Crossfire®: Onco-Nursing Best Practices for Managing AEs Related to CAR T-Cell Therapy from Treatment Center to Community
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Multiple Myeloma from the Summer Meetings
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Exploring Hot Topics in DLBCL: Sequencing CD19-Targeted Therapies, Strategies Post-CAR T Relapse, Novel Agents, and More!
View More
BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for Emerging E-Selectin Antagonists in the Management of AML
View More
Do Patients with Multiple Myeloma Still Need Autologous Stem Cell Transplantation?
View More
8th Annual Live Medical Crossfire®: Hematologic Malignancies
July 20, 2024
Register Now!
Cancer Summaries and Commentaries™: Clinical Updates in MPNs from the Summer Meetings
View More
Community Practice Connections™: Multidisciplinary Strategies for Improving Outcomes in CML from Frontline Care… and Beyond!
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Medical Crossfire®: Which Patients with Hematologic Malignancies are at Risk for Secondary Immunodeficiency (SID)… and How Can We Leverage Evidence to Improve Their Outcomes?
View More
Myeloma Management Considerations: Applying the Evidence With Monoclonal Antibody Based Regimens
View More
Crucial Conversations in R/R Multiple Myeloma: Nursing Strategies to Optimize Patient Communication and Improve Outcomes
View More
Oncology Briefings™: Coordinating the Long-Term Management of Patients With Multiple Myeloma Between Primary Care and Oncology Practices
View More
Community Practice Connections™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in AML
View More
GlobaOncology Town Hall™: Primary Investigators Present Key Abstracts in the Management of B-Cell Lymphomas with BTK Inhibitors
View More
Community Practice Connections: 7th Annual School of Nursing Oncology™
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Oncology Consultations®: Community and Academic Perspectives on PNH Management – How Do You Do It?
View More
Community Oncology Connections™: Overcoming Clinical Challenges and Embracing New Opportunities in the Management of Multiple Myeloma
View More
Cases and Conversations™: Applying Guidelines to Practice for the Management of Paroxysmal Nocturnal Hemoglobinuria
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Oncology Briefings™: Selecting Therapy for Patients with Heavily Pretreated Myeloma Based on Patient and Disease-Specific Factors
View More
Oncology Briefings™: Case Discussions in Smoldering Myeloma—To Treat or Not to Treat?
View More
Community Practice Connections™: How Can We Optimize the Real World Application of BCMA-Targeted Therapies for Our Patients with R/R Multiple Myeloma?
View More
Medical Crossfire®: How Has the Nurse’s Role Evolved in the Management of Pediatric Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas?
View More
Focusing on Key Updates on the Outlook of Acute Lymphocytic Leukemia (ALL) Management
View More
Dr Bijal Shah Describes Brexucabtagene Autoleucel Toxicity in ZUMA-3
June 11th 2021The phase 2 ZUMA-3 trial of brexucabtagene autoleucel showed that it is possible to intervene early to prevent some toxicity, said Bijal Shah, MD, associate member in the Department of Malignant Hematology at Moffitt Cancer Center.
EHA Preview: Advances, Outcomes in CAR T-Cell Therapies and Management Challenges
June 8th 2021With 5 chimeric antigen receptor (CAR) T-cell therapies approved by the FDA, and 299 agents in the pipeline, it’s no surprise that the virtual meeting of the European Hematology Association (EHA) will have a heavy presence of CAR T research being presented in sessions and posters.
Etranacogene Dezaparvovec Is Highly Unlikely the Cause of HCC in Hemophilia B Study
March 29th 2021Etranacogene dezaparvovec was "highly unlikely" to be the cause of hepatocellular carcinoma in a patient with hemophilia B enrolled in the phase 3 HOPE-B trial, according to an independent investigation.
FDA Approves Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma
March 27th 2021The FDA has approved idecabtagene vicleucel as the first BCMA-directed CAR T-cell therapy for patients with relapsed/refractory multiple myeloma after 4 or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.